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Context 
Polycystic ovary syndrome (PCOS) is a prevalent metabolic disorder, occurring in up to 10% of 
women of reproductive age. PCOS is associated with insulin resistance and cardiovascular risk. 
Androgen excess is a defining feature of PCOS and has been suggested as causally associated 
with insulin resistance; however, mechanistic evidence linking both is lacking. We hypothesized 
that adipose tissue is an important site linking androgen activation and metabolic dysfunction in 
PCOS.  
Methods  
We performed a human deep metabolic in vivo phenotyping study, examining the systemic and 
intra-adipose effects of acute and chronic androgen exposure in ten PCOS women, in comparison 
to ten body mass index-matched healthy controls, complemented by in vitro experiments. 
Results 
PCOS women had increased intra-adipose concentrations of testosterone (p=0.0006) and 
dihydrotestosterone (p=0.01), with increased expression of the androgen-activating enzyme aldo-
ketoreductase type 1 C3 (AKR1C3, p=0.04) in subcutaneous adipose tissue. Adipose glycerol 
levels in subcutaneous adipose tissue microdialysate supported in vivo suppression of lipolysis 
after acute androgen exposure in PCOS (p=0.04). Mirroring this, non-targeted serum 
metabolomics revealed pro-lipogenic effects of androgens in PCOS women only. In vitro studies 
showed that insulin increased adipose AKR1C3 expression and activity while androgen exposure 
increased adipocyte de novo lipid synthesis. Pharmacological AKR1C3 inhibition in vitro 
decreased de novo lipogenesis.  
Conclusions 
These findings define a novel intra-adipose mechanism of androgen activation that contributes to 
adipose remodelling and a systemic lipotoxic metabolome, with intra-adipose androgens driving 
lipid accumulation and insulin resistance in PCOS. AKR1C3 represents a promising novel 
therapeutic target in PCOS. 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2017  DOI: 10.1210/jc.2017-00947 
 
 
2 
This integrated in vivo and in vitro study examines the role of AKR1C3 in adipose androgen generation in 
PCOS, and how locally activated androgens exert lipotoxic effects on adipose lipid metabolism. 
INTRODUCTION 
Polycystic ovary syndrome (PCOS) is a prevalent disorder in women of reproductive age, and is 
defined by androgen excess and anovulatory infertility (1, 2). It affects 6.1-19.9% of women, 
depending on diagnostic criteria applied (3). In terms of clinical consequences, however, PCOS 
is primarily a disorder with adverse metabolic risk impact, as evidenced by a high prevalence of 
insulin resistance (4), dyslipidemia (5), and increased rates of type 2 diabetes mellitus and 
hypertension (3, 6), over and above those observed in simple obesity. Recent data also highlight 
increased rates of cardiovascular disease (7) and non-alcoholic fatty liver disease (8, 9) in 
women affected by PCOS.  
Androgen excess is a defining feature of PCOS (10); however, its origins remain 
insufficiently understood. Although traditionally perceived as a disorder of purely ovarian origin, 
it is now clear that there are also complex contributions from the adrenal and peripheral tissues to 
PCOS-related androgen excess (11, 12) (13, 14). The potent androgens testosterone (T) and 5α-
dihydrotestosterone (DHT) can be activated from androgen precursors in peripheral target tissues 
of androgen action (12, 15). The severity of androgen excess and insulin resistance in PCOS are 
closely correlated, but the direction of causality remains unclear. Insulin resistance due to 
monogenic insulin receptor mutations has been shown to be associated with a severe androgen 
excess phenotype (16). Conversely, monogenic causes of androgen excess are associated with 
adverse metabolic consequences and can present with a PCOS phenotype (17-19).  
One of the major metabolic compartments, adipose tissue, is capable of androgen generation, 
a process that is tightly regulated by a complex network of activating and inactivating enzymes 
(20). The enzyme aldo-ketoreductase type 1C3 (AKR1C3), which converts androstenedione (A4) 
to the biologically active androgen T, is abundantly expressed in adipose tissue (21), with 
increased expression in subcutaneous fat from both women with simple obesity (22) and PCOS 
(23). Previous work has shown that AKR1C3 is the only enzyme expressed in adipose tissue that 
is capable of activating A4 to T (22). The enzyme 5α-reductase type 1 (SRD5A1) activates T in 
peripheral target tissues to the most potent androgen, DHT, and is highly expressed in adipose 
tissue (24). Studies in rodent and non-human primate models show that pre- and postnatal 
androgen exposure in females leads to increased adipocyte size, enlarged visceral fat depots and 
reduced insulin sensitivity (25-27). However, human data on the effects of androgen excess on 
key processes of adipose biology, such as adipogenesis and lipid metabolism, are lacking. 
In this study, we explored the hypothesis that increased intra-adipose androgen generation by 
AKR1C3 is a central driver of adipose tissue dysfunction and lipotoxicity in PCOS. To test our 
hypothesis, we undertook a study utilizing innovative in vivo physiology tools for deep metabolic 
phenotyping in a cohort of women with PCOS and age-, sex- and BMI-matched healthy controls, 
alongside in vitro experiments defining the impact of androgens on human adipocyte biology. 
METHODS 
Study participants 
 Women with PCOS aged between 18 and 40 years were recruited from outpatient clinics 
at University Hospitals Birmingham and Birmingham Women’s Hospital. Full ethical approval 
was obtained from Edgbaston Research Ethics Committee (reference 12/WM/0206) and all 
participants provided written informed consent prior to inclusion in the study. PCOS was 
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diagnosed according to the Rotterdam European Society of Human Reproduction and 
Embryology (ESHRE) 2004 criteria, with the presence of two or more of the following: 
oligo/anovulation (Anov), clinical signs of androgen excess (AE), and polycystic ovaries (PCO) 
on ultrasound (10); however, only PCOS women with clinical or biochemical signs of androgen 
excess were recruited to the in vivo study (phenotypes AE+Anov+PCO, AE+Anov and 
AE+PCO). Other potential causes of oligomenorrhea and androgen excess were excluded by 
history, physical examination and biochemical assessment. All healthy controls were age- and 
BMI-matched, and recruited via local advertisement, with exclusion of PCOS on clinical and 
biochemical grounds. Recruitment numbers for each study group were agreed based on a priori 
power calculations; based on estimated detectable differences and standard deviations in adipose 
microdialysis data and serum androgen profiles across the DHEA challenge, a sample size of 10 
PCOS and 10 control patients was deemed sufficient to achieve 80% statistical power for the 
detection of a difference with a p-value of <0.05.  Exclusion criteria for the study were as 
follows: recent glucocorticoid treatment (within 3 months), pregnancy, age younger than 18 or 
older than 45 years, recent oral contraceptive use (within 3 months), hyperprolactinemia, thyroid 
disorders, and dysglycemia (impaired fasting glucose, impaired glucose tolerance or overt 
diabetes mellitus). PCOS women were also excluded if they had received prior treatment with 
metformin, insulin sensitizers or androgen receptor blockers. Detailed information on the clinical 
protocol is provided in Supplementary Methods and Figure 1A. Subcutaneous abdominal fat 
samples were obtained by excisional biopsy (2-3cm3, approximately 3-5g) in both PCOS and 
control women under local anesthetic and sterile conditions, 5cm lateral to the umbilicus. 
Excised adipose tissue was immediately placed in RNALater (Life Technologies, Paisley, UK) 
and stored at -20°C for subsequent RNA extraction. 
Biochemical analysis 
 Insulin (Mercodia) and serum free fatty acids (Zen-Bio) were measured using 
commercially available assays, according to manufacturer instructions. Plasma glucose was 
measured using the 2300 STAT PLUS analyzer (YSI Incorporated, Life Sciences, Ohio, USA). 
Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the 
formula [fasting glucose (mmol/L)*fasting insulin (pmol/L)/135]. Microdialysate samples were 
collected in microvials and analyzed using a mobile photometric, enzyme-kinetic analyzer (CMA 
Iscus Flex) for glucose, pyruvate, lactate and glycerol. 
Steroid metabolite analysis (adipose microdialysate, serum and cellular supernatant) 
 Androgens from adipose microdialysate, serum and cellular supernatant were measured 
by liquid chromatography/tandem mass spectrometry (LC-MS/MS) using a Waters Xevo mass 
spectrometer with Acquity uPLC system, as described previously (11). Measurement of T, A4 
and DHEA was facilitated by serum steroid oxime analysis, and carried out in positive mode. T, 
A4 and DHEA were extracted from 150µL interstitial fluid, 400µL serum and 1mL cellular 
supernatant via liquid-liquid extraction with 1, 2 and 4mL of tert-butyl-methyl-ether (MTBE), 
respectively. This was followed by derivitization into oximes. Serum DHEAS was extracted 
from 20µL of serum with 100µL acetonitrile, before evaporation under constant nitrogen flow 
(28).  
For each LC-MS/MS assay, chromatography was optimized using a methanol/water (0.1% 
formic acid) gradient system. Steroids were quantified according to a linear calibration series 
with appropriate internal standards. Individual steroids were identified by matching retention 
times and two mass transitions in comparison to a deuterated reference compound.  
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 Measurement of urinary steroid metabolite excretion by GC/MS is described in the 
Supplementary Methods.  
Non-targeted serum metabolomics 
 We carried out mass spectrometry-based, non-targeted metabolome analysis in negative 
and positive ion mode at the Phenome Centre Birmingham, UK. In-depth methodology for non-
targeted serum metabolomic profiling has been published by our group previously (24) and the 
full protocol is available in the Supplementary Methods.  
Primary human adipocyte culture 
 Paired primary subcutaneous preadipocytes were isolated from adipose tissue obtained 
from healthy, non-diabetic women aged 18-45 years undergoing elective abdominal laparotomies 
for non-malignant, non-inflammatory disease, using methods described previously (29). Samples 
from women with diabetes or treated with systemic glucocorticoids in the last 3 months were 
excluded. Sample collection was facilitated via the University of Birmingham Tissue 
Biorepository. Briefly, adipose tissue samples were dissected into 2-3mm3 pieces and digested 
with type II collagenase (Sigma Aldrich, Dorset, UK) at 37°C for 60 minutes. Samples were then 
centrifuged at 12,000rpm for 5 minutes. Preadipocytes were extracted from a pellet containing 
the stromovascular components and resuspended in DMEM/nutrient mixture F12, containing 
fetal bovine serum (FBS) 10% (Sigma-Aldrich, UK) and penicillin-streptomycin 1% (Applied 
Biosystems, UK). Preadipocytes were proliferated to confluence before chemically-defined 
culture media was applied for 14 days to stimulate differentiation into adipocytes. Differentiation 
was initiated by washing the cells in serum-free media, followed by culture with differentiation 
media (DMEM-F12 media containing biotin 33µM, pantothenate 17µM, T3 1nM, insulin 
167nM, cortisol 1µM and rosiglitazone 1µM. AKR1C3 activity was determined by generation of 
testosterone after incubation of cells with 200nM of the testosterone precursor androstenedione 
(A4) in serum-free media for 24 hours.     
Simpson-Golabi-Behmel syndrome (SGBS) pre-adipocyte cell line culture 
 Conditions for culture and differentiation of the human pre-adipocyte SGBS cell line are 
described in the Suppl. Appendix.   
Functional studies of lipid metabolism  
 A detailed description of methodology for de novo lipogenesis, β-oxidation and free fatty 
acid uptake is provided in Suppl. Appendix.  
Statistics 
 The Statistical Package for the Social Sciences (SPSS, Version 22, Chicago, Ill., USA) 
was used for data analysis. Data are presented as mean ± SEM unless otherwise stated. Baseline 
clinical and biochemical data were not normally distributed and are therefore presented as 
median and interquartile range. AUC analysis was carried out using the trapezoidal method. For 
comparison of single variables, t tests (paired or unpaired as appropriate) were used, or 
nonparametric equivalents where data was not normally distributed. One-way ANOVA with post 
hoc Tukey testing was used for multiple comparisons between different groups. For realtime 
PCR data, statistical analysis was performed on mean ∆ct values only. Correlation testing was 
performed using Pearson’s correlation coefficient or Spearman’s test as appropriate. Serum 
metabolomics data was analyzed by applying univariate (Mann-Whitney U test or Wilcoxon 
signed rank test) analysis after normalization to total peak area per sample.  
RESULTS 
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Systemic androgen concentrations and measures of insulin resistance 
 Ten women with PCOS and 10 healthy, sex-, age- and body mass index-matched 
volunteers were recruited to an in vivo physiology study for deep metabolic phenotyping (see 
Fig. 1A and for detailed protocol description the Suppl. Appendix); clinical and biochemical 
characteristics of both groups are summarized in Suppl. Table 1.  
Baseline circulating androgens, measured by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS), were all significantly higher in PCOS than in controls, as was 
insulin resistance assessed by HOMA-IR (p=0.003) (Suppl. Table 1).  Similarly, truncal fat 
mass and volume on body composition imaging by dual x-ray absorptiometry (DXA) were 
increased in the PCOS group compared to matched controls (Suppl. Table 1). These findings 
demonstrate the expected systemic androgen excess, insulin resistance, and increased visceral 
adiposity in PCOS subjects in comparison to sex-, age- and body mass index-matched controls. 
Adipose tissue-specific androgen excess in PCOS 
To explore in vivo androgen concentrations in the adipose tissue metabolic compartment, we 
inserted a microdialysis catheter into the abdominal subcutaneous adipose tissue of each 
participant, which allowed the sampling of adipose tissue interstitial fluid across a semi-
permeable membrane. We employed LC-MS/MS to measure androgens in adipose 
microdialysate in both PCOS and control subjects, representative of in vivo intra-tissue androgen 
homeostasis.  
Adipose tissue concentrations of the androgen precursors DHEA (p=0.01) and A4 (p=0.01) 
and the active androgen T (p=0.0006) were significantly increased in PCOS subjects (Fig. 1B-
D). The most potent androgen DHT was quantifiable in adipose interstitial fluid in all 10 PCOS 
patients and in six of the 10 control patients, with significantly higher concentrations in PCOS 
(4.5±1.7 vs 0.9±0.3nmol/l, p=0.01, Fig. 1E). Adipose tissue microdialysate concentrations of 
DHEA, A4 and DHT all correlated positively with HOMA-IR (R=0.51, p=0.02, R=0.54, p=0.01 
and R=0.44, p=0.04, respectively), while intra-adipose T correlated positively with fasting 
insulin levels (R=0.49, p=0.04) (for complete correlation analysis, see Suppl. Table 2).  
Of note, concentrations of the androgen precursors DHEA and A4 were higher in serum, i.e. 
in systemic circulation, than in adipose tissue in both PCOS and control women (Fig. 1B+C). By 
contrast, intra-adipose concentrations of the androgen receptor-activating androgens T and DHT 
were significantly higher than serum levels in PCOS women (p<0.0001, Fig. 1D+E). Androgen 
concentrations in control women did not differ between circulation and adipose tissue.  
The intra-adipose ratio of T to A4, reflective of AKR1C3 activity, was significantly higher 
than in serum (p<0.0001, Fig. 1F) in the PCOS patients but not in the BMI-matched controls 
(data not shown). Similarly, in the PCOS women, the intra-adipose ratio of DHT to T, reflecting 
5α-reductase activity, was significantly higher than in serum (p<0.0001, Fig. 1G).  
Subcutaneous adipose tissue biopsies from PCOS and control women were used for mRNA 
expression analysis by realtime qPCR. This showed significantly increased AKR1C3 mRNA 
expression in subcutaneous fat from PCOS women (mean ∆ct PCOS 12.1±0.2 vs 13.1±0.4 in 
controls, p=0.04, Fig. 1H). Conversely, we found significantly decreased intra-adipose 
expression of SRD5A1 in PCOS women (mean ∆ct PCOS 16.1±0.4 vs. 14.3±0.4 in controls, 
p=0.005, Fig. 1I), indicating that AKR1C3 is the major driver of intra-adipose androgen excess 
in PCOS. 
An acute oral androgen challenge suppresses in vivo lipolysis in PCOS adipose tissue  
To examine the effect of androgens on in vivo adipose tissue metabolism, study participants 
received an oral dose of the androgen precursor DHEA at baseline, followed by sampling of 
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serum and adipose tissue microdialysate every 30 minutes for 4 hours. We have previously 
shown that this DHEA challenge test results in rapid generation of downstream androgens that 
can be detected in serum and urine (15, 30). Following the oral ingestion of 100mg DHEA, we 
measured circulating androgens by LC-MS/MS and documented significantly higher areas under 
the curve (AUC; mean±SEM nmol/L.min) in women with PCOS for serum DHEA (7437±720 vs 
4317±654 in controls, p=0.005), A4 (258±65 vs 63±25 in controls, p=0.01), and T (2507±237 vs 
1556±303 in controls, p=0.01). Increased circulating concentrations of T sulphate and DHT 
glucuronide after DHEA exposure in both controls and PCOS (all p<0.0001, Fig. 1J-K) further 
documented the extent of acute androgen generation following DHEA administration. This 
demonstrates that we exposed both groups to an equivalent acute androgen challenge on the 
background of chronic androgen excess (PCOS) or normal circulating androgen concentrations 
(controls). 
 To examine the in vivo metabolic impact of this androgen load, we measured markers of 
insulin sensitivity and lipid metabolism at baseline and after acute DHEA exposure, looking at 
both systemic (serum) and tissue-specific (adipose microdialysate) outcomes (Fig. 2). Plasma 
glucose levels were similar at baseline and across the DHEA challenge in both PCOS and 
controls (Fig. 2A). Baseline fasting insulin was significantly increased in PCOS (Suppl. Table 
1), but AUC values for insulin across the DHEA challenge (pmol/L.min) did not differ 
significantly between PCOS and controls (14672±4120 vs 8043±2958, p=0.21, Fig. 2B). There 
was no difference in baseline or AUC values for serum free fatty acids between the two groups 
(Fig. 2C).  
 Assessing the adipose tissue-specific in vivo metabolic response, we measured metabolic 
markers in adipose microdialysate. Adipose pyruvate, lactate and glucose did not differ 
significantly between PCOS women and controls at baseline and in response to DHEA (Fig. 2D-
F). However, AUC values for glycerol (µM.min) significantly decreased in PCOS patients after 
DHEA (PCOS 35347±4781 vs 22310±3577 in controls, p=0.04) (Fig. 2G-H), consistent with 
decreased lipid mobilization in PCOS in response to acute androgen exposure.  
Androgen excess induces distinct changes in the circulating metabolome in PCOS  
  Mass spectrometry-based non-targeted metabolome analysis was employed to determine 
differences in global metabolic phenotype in PCOS serum compared to controls before and after 
DHEA administration. At baseline, we identified 119 metabolites that were statistically different 
(p<0.01) when comparing PCOS to control subjects. Significantly perturbed metabolite classes 
in PCOS included diacylglycerides, fatty acids and oxidized fatty acids, sterol and steroid 
metabolites, as well as glycerophospholipids (GPL) and lysoglycerophospholipids (LGPL) (Fig. 
3A+B); other classes included aromatic amino acid metabolism, ceramides and sphingolipids, 
and ubiquinone/quinone metabolism. Both oxidized and non-oxidized fatty acids and the 
majority of diacylglycerides showed higher concentrations in control subjects, while GPL and 
LGPL concentrations were higher in PCOS subjects.  
 In response to DHEA administration, i.e. acute androgen exposure, the metabolome of 
PCOS patients (with a background of chronic androgen excess) and that of BMI-matched 
controls (with normal baseline androgens) showed distinct changes (Fig. 3C-F, Suppl. Table 3). 
DHEA induced highly significant changes in 15 diacylglycerides, 32 fatty acids and 16 oxidized 
fatty acids in the control group; in PCOS women, changes were observed in 16 diacylglycerides, 
31 fatty acids and 19 oxidized fatty acids. In all cases, DHEA reduced circulating concentrations 
of diacylglcyerides and oxidized and non-oxidized fatty acids compared to baseline, in both 
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PCOS and controls, a demonstration of the potent effects of androgens in the regulation of lipid 
metabolism. 
Of note, the majority of GPLs and LGPLs, which were significantly increased in PCOS at 
baseline (Fig. 3B), showed a diametrically opposed metabolic response to the acute androgen 
challenge, with significant further upregulation in PCOS and downregulation in the BMI-
matched health controls (Fig. 3E-F, Suppl. Table 3), indicating a distinctly different metabolic 
response to androgens in PCOS. 
Androgens promote adipose lipid accumulation in vitro 
 To dissect the observed effects in further detail, we utilized a human pre-adipocyte cell 
line, SGBS, previously validated as a model of human subcutaneous adipocyte biology (31).  To 
determine the role of androgens in adipose lipid metabolism, differentiated adipocytes were 
treated with increasing concentration of T and DHT. Androgen treatment for 24 hours resulted in 
a dose-dependent increase in mRNA expression of acetyl-CoA-carboxylase (ACC1), the rate-
limiting step in lipogenesis, but not ACC2 (fold change vs. untreated control: T 20nM 1.3±0.1, 
p=0.02; T 40nM 1.6±0.1, p<0.001; DHT 10nM 1.8±0.3, p=0.006; DHT 20nM 2.2±0.8, p=0.01, 
Figure 4A).  
Consistent with upregulation of ACC1 mRNA expression, T 40nM significantly increased de 
novo lipogenesis in SGBS cells in the absence of insulin, as measured by uptake of 1-[14C]-
acetate incorporation into lipid (150.4±7.3% of untreated cells, p=0.02, Figure 4B). This effect 
was also observed with DHT 20nM (121.9±8.4%, p=0.03), confirming it as androgen-mediated 
as DHT, in contrast to T, cannot be converted to oestrogens via aromatase activity. Insulin (5nM) 
expectedly resulted in a significant increase of de novo lipogenesis compared to control 
incubations without insulin (250.0±19.1%, p=0.009). However, there was no additional effect of 
insulin when added to the incubations with androgens (p=0.9 for both T and DHT). 
 In SGBS cells, exposure to DHT 20nM significantly decreased β-oxidation of fatty acids 
compared to untreated control cells (83.2±5.9%, p=0.03) (Figure 4C) while we did not observe 
androgen effects on free fatty acid uptake (Figure 4D).  
AKR1C3 links adipose androgen excess and lipid accumulation in PCOS 
To examine the role of insulin in AKR1C3-mediated androgen generation, we examined 
expression and activity of AKR1C3 in primary human adipocytes and SGBS cells before and 
after insulin treatment. AKR1C3 mRNA expression increased significantly across differentiation 
from pre-adipocyte (day 0) to the mature adipocyte (day 14) phenotype in both subcutaneous and 
omental female adipocytes (mean ∆ct for subcutaneous fat: 16.4±0.5 [preadipocytes] vs 11.7±1.3 
[adipocytes], p=0.03; mean ∆ct for omental fat: 19.5±0.1 [preadipocytes] vs 11.4±1.1 
[adipocytes], p=0.001). AKR1C3 activity, as determined by generation of T after incubation of 
cells with 200nM A4 for 24 hours, was significantly upregulated across adipocyte differentiation 
in both subcutaneous and omental fat depots (p=0.02 and p=0.04, respectively).  
 AKR1C3 mRNA expression increased significantly in both SGBS and primary female 
subcutaneous adipocytes (n=3) after exposure to insulin 20nM (p=0.03 and p=0.04, respectively, 
Figure 5A+C), but not in primary female omental adipocytes (n=3, p=0.18). Similarly, AKR1C3 
activity was significantly increased by insulin exposure at doses in SGBS cells and primary 
female subcutaneous adipocytes (Figure 5B+D), but not in primary omental adipocytes.  
Selective pharmacological AKR1C3 inhibition with 3-4-trifluoromethyl-phenylamino-
benzoic acid (10µM for 24 hours) significantly reduced generation of active androgen T from the 
androgen precursor A4. This was observed in both control adipocytes and those treated with 
10nM insulin (100% [control] vs 59 ± 3% [inhibitor], p<0.0001; 131±10% [10nM insulin] vs 
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77±16% [inhibitor], p=0.02, Figure 5E). Adipocytes treated with 100nM A4 showed 
significantly increased de novo lipogenesis (179.4±21.5%, p=0.002); this effect was significantly 
attenuated by co-incubation with the selective AKR1C3 inhibitor (p=0.04, Figure 5F). Hence, 
disruption of AKR1C3-mediated androgen generation ameliorates androgen-mediated adverse 
effects on adipocyte lipogenesis, thereby mechanistically linking androgen excess and insulin 
resistance. 
DISCUSSION  
 Utilizing a human in vivo physiology approach, we have demonstrated an adipose tissue-
driven mechanistic link between androgen excess and lipid metabolism in PCOS. We used mass 
spectrometry to determine both systemic and adipose tissue androgen concentrations, revealing 
significantly increased androgen synthesis in PCOS adipose tissue, alongside increased 
expression and activity of the androgen-activating enzyme AKR1C3. This demonstrates the 
significant capacity of adipose tissue to act as a source of androgen excess in PCOS. 
Furthermore, androgens promoted in vitro lipid accumulation in human adipocytes, and 
suppressed in vivo lipolysis in women with PCOS. The net effect of this is promotion of 
adipocyte hypertrophy. Enlarged, ‘lipid-overloaded’ adipocytes are insulin resistant (32), fueling 
the adverse metabolic phenotype observed in PCOS, with lipid overspill and lipotoxicity in other 
organs such as liver. We could show that in vitro inhibition of AKR1C3 decreased androgen 
excess and subsequently de novo lipogenesis, identifying AKR1C3 as a novel target for 
therapeutic intervention in PCOS.   
  Several 17β-hydroxysteroid dehydrogenase enzymes are capable of activating 
androstenedione (A4) to testosterone (T), but of those only AKR1C3 is expressed in human 
adipose tissue (Quinkler et al., 2004). Interestingly, expression of the androgen-inactivating 
enzyme HSD17B2, which is capable of inactivating T to A4 and has been detected in omental 
adipose tissue (33), was not detectable in subcutaneous adipose tissue in the current study or in 
previous work by our group (22). Our studies reveal the androgen-activating enzyme AKR1C3 
as the predominant driver of active androgen generation in adipose tissue of PCOS patients. 
AKR1C3 is a crucial enzyme in androgen biosynthesis in the adrenal, ovary, prostate and 
adipose tissue (34), and AKR1C3 single nucleotide polymorphisms have been reported as 
associated with an increased prevalence of PCOS and hyperandrogenism in women (35). BMI 
differed slightly between the control and PCOS groups in this study (medians 33.1 v 28.6kg/m2), 
although this difference did not show statistical significance, possibly due to the size of the 
cohorts. With this minor caveat in mind, our finding of increased AKR1C3 expression and 
activity confirm and expand the significance of results from a previous study describing 
increased AKR1C3 mRNA expression in subcutaneous adipose tissue of PCOS women (23).  
In our in vitro studies, we conclusively demonstrated that AKR1C3 expression is regulated 
by insulin, mechanistically linking androgen excess and insulin resistance, the two major 
metabolic features in PCOS. We found that insulin increased AKR1C3 expression and T 
generation in vitro, and in vivo we found a significant correlation between adipose tissue T and 
circulating insulin. Some previously published evidence had provided preliminary evidence for 
the potential regulation of adipose androgen metabolism by insulin. The fasting induced 
transcription factor Kruppel-like factor 15 (KLF15) is crucially required for adipocyte 
differentiation (36), represents a key regulator of gluconeogenesis (37) and has been recently 
shown to represent a molecular link between glucose metabolism and lipogenesis (38). The 
AKR1C3 promoter contains a KLF15 binding site and in vitro overexpression of KLF15 results 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2017  DOI: 10.1210/jc.2017-00947 
 
 
9 
in increased AKR1C3 promoter activity and T formation by adrenal NCIH295R cells (39). 
Intriguingly, we found increased expression of both AKR1C3 and KLF15 in the subcutaneous 
adipose tissue biopsies in our PCOS patients. 
In this study, we demonstrated the functional impact of chronic and acute androgen exposure 
on the regulation of adipose tissue lipid metabolism, demonstrating suppressed lipolysis in vivo 
and increased lipogenesis in vitro. Data from non-targeted serum metabolomics support this 
observation of enhanced lipogenesis in PCOS. Serum metabolomics also revealed significantly 
increased concentrations of glycerophospholipids (GPL) and lysoglycerophospholipids (LGPL) 
in women with PCOS but not in controls; the acute androgen challenge yielded a further increase 
of these metabolites in PCOS patients, whereas concentrations in BMI-matched controls 
decreased. This demonstrates distinctly different metabolic responses to androgens in PCOS and 
controls and suggests that androgen excess plays a distinct in role in creating a lipotoxic 
metabolic environment. Both GPL and LGPL previously identified as markers of risk and 
progression in non-alcoholic fatty liver disease (40), which is more prevalent in women with 
PCOS.  
 In conclusion, we have shown evidence that intra-adipose androgen excess and 
dysfunctional adipose lipid metabolism are causally linked drivers of adverse metabolic risk in 
PCOS. We have described putative novel mechanisms by which androgens regulate adipose 
tissue function, lipid metabolism and fat mass, and have highlighted, at the level of the 
adipocyte, the enzyme AKR1C3 as a key regulator linking insulin resistance and androgen 
excess in PCOS. We postulate that a vicious circle in adipose tissue drives metabolic risk in 
PCOS (Fig. 6A), consisting of increased androgen generation in adipose tissue by AKR1C3, 
subsequent lipid accumulation and increased fat mass, resulting in systemic insulin resistance 
and lipotoxic organ damage, with androgen generation further exacerbated by hyperinsulinemia. 
We have shown that selective in vitro inhibition of AKR1C3 significantly reduced androgen-
induced de novo lipogenesis. This suggests that local generation of T from A in subcutaneous 
adipose tissue by AKR1C3 is an important driver of androgen-mediated lipid accumulation. 
The disruption of this vicious circle should now be studied in patients with PCOS, employing 
selective pharmacological inhibition of AKR1C3. Murine models are not suitable for the 
exploration of human androgen synthesis and metabolism as steroidogenic enzymes such as the 
17β-hydroxysteroid dehydrogenase family are very differently organized in mice and men. In 
humans, AKR1C3 is a central gatekeeper enzyme not only in classic androgen synthesis, but also 
in the alternative pathway to DHT synthesis (41) and the 11-oxygenated androgen pathway (42). 
Recent work (43) has shown that 11-oxygenated androgens represent the majority of circulating 
androgens in PCOS, including 11-keto-testosterone, which has 3-4 fold higher serum 
concentrations than T in PCOS patients, while activating the androgen receptor with similar 
potency. Therefore, selective AKR1C3 inhibition is likely to provide most efficient control of 
PCOS-related androgen excess (Fig. 6B). In addition, based on our findings, inhibition of 
AKR1C3 is likely to exert beneficial effects on the adverse metabolic phenotype in PCOS, 
through amelioration of both circulating androgen burden and abnormal adipose tissue biology. 
In conclusion, AKR1C3 represents a highly promising, novel therapeutic target in women with 
PCOS. 
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Figure 1: Circulating androgens and in vivo intra-adipose tissue androgen synthesis in 
PCOS (n=10) and age- and body mass-index healthy controls (n=10). (A) Deep metabolic in 
vivo phenotyping protocol with serum and adipose microdialysate sampling every 30 minutes for 
4 hours. Following baseline sampling, an acute androgen challenge was administered by oral 
intake of a 100mg dose of the androgen precursor dehydroepiandrosterone (DHEA) at 0min; 
schematic represents the classic androgen synthesis pathway from DHEA to active androgens. 
(B-E) Serum and in vivo intra-adipose concentrations of DHEA, androstenedione (A4), 
testosterone (T) and 5α-dihydrotestosterone (DHT) in controls (white circles) and PCOS women 
(red circles). Lines represent the median of each group. (F-G) Steroid ratios reflective of the 
conversion of A4 to T (T/A4) and the conversion of T to DHT (DHT/T) as measured in serum 
and adipose tissue microdialysate of PCOS women. Lines represent the median of each group. 
(H-I) Relative mRNA expression of the androgen-generating enzymes AKR1C3 (converting A4 
to T) and SRD5A1 (converting T to DHT) in subcutaneous abdominal adipose tissue from PCOS 
and controls (n=7 for each). Lines represent the median of each group. (J-K) Serum T sulfate 
and DHT glucuronide concentrations before and 150 min after oral administration of the 
androgen precursor DHEA. Boxes represent median and 25th to 75th centile, whiskers represent 
10th and 90th centile. Significance levels *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 (Mann 
Whitney test). All steroid concentrations were measured by mass spectrometry-based assays. 
Figure 2: Impact of acute oral androgen challenge (DHEA 100mg) on in vivo metabolic 
markers in serum and adipose tissue microdialysate. Serum glucose, insulin and free fatty 
acids (A-C) and intra-adipose pyruvate, glucose, lactate and glycerol levels (D-G) in PCOS 
(n=10, dark line, red circles) and control women (n=10, dotted line, white circles across the 
DHEA challenge test (mean±SEM). Time of oral administration of 100mg DHEA indicated by 
arrow. Panel H, area under the curve (AUC) for glycerol between 120 and 240 minutes after 
androgen exposure in the PCOS group compared to controls. *p<0.05 (Mann Whitney test). For 
further details see Supplemental Methods. 
Figure 3: Baseline differences and changes induced in the non-targeted serum metabolome 
by acute androgen exposure in women with PCOS (n=10) and age- and BMI-matched 
healthy control women (n=10). Panel A, the number of serum metabolites associated with lipid 
and steroid metabolism observed to be significantly different (p<0.01) at baseline between 
control and PCOS subjects. Panel B, Significantly different glycerophospholipid (GPL) and 
lysoglycerophospholipid (LGPL) metabolites between PCOS women and controls at baseline.  
Panels C-D, Metabolic responses lipid and steroid metabolite following exposure of controls and 
PCOS subjects to an acute androgen challenge (DHEA 100mg administered orally at 0min; 
serum metabolome analysis carried out with 150min serum sample, representative of the 
maximum of circulating androgen concentrations after DHEA).  Panels E-F, Differential 
response of GPL and LGPL to the acute DHEA challenge in comparison of controls and PCOS 
women.  Data matrix analyzed applying univariate (Wilcoxon signed rank test) after 
normalization to total ion current per sample. Abbreviations: DAG, diacylglycerides; FA, fatty 
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acids; GPL, glycerophospholipids; LGPL, lysoglycerophospholipids; OFA, oxidized fatty acids; 
SS, sterols and steroid metabolites. 
Figure 4: The effects of androgens on adipose lipid metabolism in the human pre-adipocyte 
SGBS cell line. Panel A, The effect of androgens [testosterone (T) light blue bars, 5α-
dihydrotestosterone (DHT) dark blue bars] on the mRNA expression of Acetyl-CoA carboxylase 
1 (ACC1), the main provider of malonyl-CoA for fatty acid synthesis.  Panel B, Effect of T and 
DHT on de novo lipogenesis, determined by incorporation of 14C acetate into lipid.  Panel C, 
Effects of T and DHT on β-oxidation, determined by 3H20 release from 3H-palmitate.  Panel D, 
Effects of androgens on free fatty acid uptake.  All data are presented as the mean±SEM of n=3-
5 experiments. Significance levels *p<0.05; **p<0.01; ***p<0.001 compared to control 
(ANOVA with post hoc Tukey test).  
Figure 5: Expression, activity and inhibition of the androgen-activating enzyme aldo-
ketoreductase type 1C3 (AKR1C3) in subcutaneous adipose tissue. Panels A-D, Expression 
and activity of AKR1C3 with and without insulin stimulation in the human pre-adipocyte SGBS 
cell line and primary subcutaneous adipocytes from women undergoing elective surgery. Panel 
E, Effect of pharmacological AKR1C3 inhibition by 3-4-trifluoromethyl-phenylamino-benzoic 
acid (10µM) for 24 hours (grey bars) on adipose androgen generation, assessed as conversion of 
androstenedione to testosterone. Panel F, Impact of pharmacological AKR1C3 inhibition on 
androstenedione-mediated de novo lipogenesis. All data are presented as the mean±SEM of n=3-
5 experiments. Significance levels *p<0.05; **p<0.01; ***p<0.001 (ANOVA with Tukey post-
hoc test).  
Figure 6: Schematic representation of the proposed mechanistic link between androgen 
excess, insulin resistance and lipotoxicity in polycystic ovary syndrome (A) and graphical 
representation of the major human androgen biosynthesis pathways (B).  AKR1C3 plays a 
central gatekeeping role in androgen activation in the classic androgen synthesis pathway and the 
alternative (‘backdoor’) pathway to 5α-dihydrotestosterone as well as the 11-oxygenated 
androgen synthesis pathway. Active androgens capable of activating the androgen receptor 
highlighted in blue boxes and white font. 
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